Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Summit Therapeutics Inc. (SMMT)

16.03 -0.17 (-1.05%)
At close: October 30 at 4:00:00 PM EDT
15.98 -0.05 (-0.32%)
After hours: October 30 at 7:56:30 PM EDT
Trade SMMT on Coinbase
Chart Range Bar
Loading chart for SMMT

What's happening with SMMT?

2m ago
Powered by Yahoo Scout

Summit Therapeutics is expanding ivonescimab development across biliary tract cancer, kidney cancer, and combination immuno-oncology. A China Phase III study reported stronger survival and response outcomes against a durvalumab-based regimen, while an AI pathology agreement may support patient selection research. The company also faces a near-term regulatory milestone for its lung-cancer application.

Powered by Yahoo Scout
  • Previous Close 16.20
  • Open 16.03
  • Bid 12.56 x 200
  • Ask 14.55 x 200
  • Day's Range 15.56 - 16.43
  • 52 Week Range 12.07 - 29.23
  • Volume 3,500,335
  • Avg. Volume 6,070,423
  • Market Cap (intraday) 12.788B
  • Beta (5Y Monthly) -1.52
  • PE Ratio (TTM) --
  • EPS (TTM) -1.11
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 30.23
  • Zacks Rating Neutral

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

www.smmttx.com

265

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SMMT
8.35%
S&P 500 (^GSPC)
10.73%

1-Year Return

SMMT
14.00%
S&P 500 (^GSPC)
11.11%

3-Year Return

SMMT
732.73%
S&P 500 (^GSPC)
81.91%

5-Year Return

SMMT
210.66%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -162.09M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-150M
-100M
-50M
0
0.0%

Analyst Insights

View More

Top Analyst

Stifel
75/100
Latest Rating
Buy

Analyst Price Targets

11.91
30.23 Average
16.03 Current
43.78 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/1/2026
Analyst Barclays
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 18 -> 20

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    12.92B

  • Enterprise Value

    12.25B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    20.40

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -101.61%

  • Return on Equity (ttm)

    -192.51%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -856.09M

  • Diluted EPS (ttm)

    -1.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    690.68M

  • Total Debt/Equity (mrq)

    3.24%

  • Levered Free Cash Flow (ttm)

    -139.68M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

16.03 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 06/15/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 06/05/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 09/12/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 03/28/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: